The concept of consuming microorganisms in the treatment of a medical condition and in health maintenance has gained much attraction, giving rise to an abundance of medical claims and of health supplements. This study identified relevant clinical questions on the therapeutic use of probiotics and reviewed the literature in irritable bowel syndrome, inflammatory bowel disease, impaired intestinal immunity, liver disease, intestinal infections, and common childhood digestive disorders. Statements were developed to address these clinical questions. A panel of experienced clinicians was tasked to critically evaluate and debate the available data. Both consensus and contentious statements are presented to provide to clinicians a perspective on the potential of probiotics and importantly their limitations.
Background
There is emerging evidence that intervention through manipulation of the individual's microbiome can lead to medically relevant and meaningful benefit. At the most extreme end of the spectrum, and yet, with one of the strongest evidence of therapeutic efficacy, is the use of fecal microbiota transplant in the treatment of Clostridium difficile infection. 1 At the broadest level, the term "probiotics" is used to describe products containing microorganisms purported to have therapeutic benefits for the consumer. Probiotics are a heterogeneous class of products with a wide variability of microbial species and quantity. Probiotics have been proposed for a wide spectrum of conditions in health and disease states. While many of these products are available as health supplements, physicians are frequently asked by patients to make a recommendation. In Canada (http://www.probioticchart.ca/) and in the USA (http:// usprobioticguide.com/), there are app tools to guide physicians on the level of evidence supporting the role of probiotics for different health indications.
In the absence of a regional food and medicine administration in the Asia-Pacific region, and taking account of differences in product availability, and differences in health and disease priorities in our region, the South East Asian Gastro-neuro Motility Association (SEAGMA) convened a panel of interested clinician scientists and clinicians of various specialties (gastroenterology 15, pediatrics 4, family medicine 3), practicing in academic-tertiary centers (n = 12) and private medical centers (n = 10), from five countries (Singapore, Malaysia, Thailand, Indonesia, and the Philippines), to develop a set of statements to guide health-care professionals in evaluating efficacy and safety of probiotic therapy.
Methods
We decided at the start to limit our scope to the role of probiotics in digestive health and gastrointestinal disorders comprising irritable bowel syndrome (IBS), inflammatory bowel disease, impaired intestinal immunity, liver disease, intestinal infections, and common childhood digestive disorders. We adopted the Delphic method beginning with a resource panel of six experts (K. A. G., W. W. R. L., K. L. L., C. J. O., S. H. Q., and Y. Y. D.; refer to Data S1 for full qualifications) in these areas to develop structured questions that reflect clinically relevant issues pertaining to the use of probiotics (Table 1) . The resource panel then reviewed the questions, rated and rank-ordered in terms of priorities, and after an extensive review of the literature, with justification based on relevance and available evidence, formulated 20 statements addressing these questions. 2 These statements, levels of evidence, supporting papers, and explanatory notes were then circulated to a wider audience of clinicians in our region. A preliminary voting by email was obtained. A face-to-face meeting was held on March 3, 2017, as part of the South-East Asia Gastro-Neuro Motility Association Scientific Meeting in Ipoh, Malaysia. During this meeting, all statements were presented, reviewed, and debated before a final vote was taken.
Voting scheme. Participants in both the email consultation process and the face-to-face meeting were asked to vote using the schema of the Canadian Task Force on the Periodic Health Examination  3 (see Table 2 ). Statements were deemed accepted if at least 80% of the respondents voted either complete acceptance or acceptance with some reservations.
Results
The statements receiving consensus support from the group are listed in Table 3 , while the statements that did not obtain consensus support are listed in Table 4 . Details of the voting and discussions are listed by the following statements. 5 and an RCT with Escherichia coli Nissle 1917 essentially failed to show significant advantage over placebo. 6 Differences may also exist between adult and pediatric patient populations. In clinical trials of Lactobacillus rhamnosus GG, efficacy was found for childhood IBS 7 but not for adult IBS as a single species probiotic treatment, 8, 9 although multi-species probiotics containing LGG had demonstrated efficacy in adult IBS subjects. [10] [11] [12] [13] Similarly, in the prevention of antibiotic-associated diarrhea, meta-analysis demonstrated efficacy for L. rhamnosus GG in children but not in adults. 14 Comments. The dose used does matter, but more is not always better. An RCT of three doses of B. infantis in IBS found improvement in global symptom relief only with the medium dose but not with the highest and smallest doses. 16 Another with multi-species I.31 for the treatment of IBS found significant improvement over placebo, with a trend for greater improvement in the low dose over the high dose. 17 In the treatment of mild-moderate ulcerative colitis to achieve remission, an RCT using VSL#3 at a dose of 3.6 × 10 12 colony forming unit (CFU)/day × 8 weeks just failed to show superiority over placebo (remission rates 47.7% vs 32.4%; P = 0.069), 18 while another study using VSL#3 at a higher dose of 7.2 × 10 12 CFU/day × 12 weeks was able to achieve superiority (remission rates 42.9% vs 15.7%; P < 0.001). 19 It should be noted that these two studies were conducted in different countries: one in Europe and one in Asia. A total of 95% of votes cast in the pre-voting and 100% of the post discussion votes were in support of the statement. The strong and consistent agreement reinforces the strength of this recommendation. Comments. Probiotic products classified as health supplements are not subject to approvals, licensing, or registration.
20 Table 3 The statements accepted by consensus Probiotics are not all the same. Appropriate dosing, as guided by clinical evidence, is important to achieve intended clinical effect of a probiotic treatment. The quality and health claims of probiotics classified as health supplements are undetermined. Probiotics have limited value in inducing remission in ulcerative colitis. Probiotics are useful in maintaining remission in chronic pouchitis. Probiotics have no role in inducing or maintaining remission in Crohn's disease. Probiotics do not increase the risk of spontaneous bacterial peritonitis or sepsis and are safe in patients with both compensated and decompensated liver cirrhosis. Probiotics are effective in reducing radiotherapy-induced diarrhea. Probiotics are beneficial but not essential in the treatment of acute gastroenteritis in children.
Probiotics decrease the incidence of antibiotic associated diarrhea in children.
Probiotics are not useful in constipation in children.
There is currently no role of probiotics in managing childhood obesity. Unlike medicines, health supplements are not assessed for their effectiveness and may not have efficacy data from stringent clinical trials. Benefits are often assumed based on the usage of known constituents, rather than from clinical trials. Microbiological evaluations of commercial probiotic products have shown inconsistencies between the content claimed on the label and actual probiotic strain identified, and sizeable loss of microbial load was observed during storage. [21] [22] [23] [24] Notwithstanding the relatively low grade of evidence, the strong and consistent agreement (96% pre-voting and 100% post discussion) reflects the sentiment that, until and unless more stringent regulation is imposed (unlikely in the foreseeable future), those in the health supplements industry who are willing to invest in clinical research will be the exception rather than the rule. Comments. The strong rejection (72%) is because available evidence did not allow us to determine whether addition of prebiotics in a probiotic formulation, that is, a synbiotic, will provide additional clinical benefit compared with giving the probiotic alone. In order to evaluate this, it is necessary to have studies comparing the therapeutic effect of a synbiotic with a standalone probiotic; such studies are limited. For IBS, a meta-analysis did not support symptomatic improvement in IBS with synbiotics. 25, 26 For traveler's diarrhea, one RCT each of fructo-oligo-saccharides and of galacto-oligosaccharides (both considered to be prebiotics) found conflicting results. 27, 28 For ulcerative colitis, one open-label study suggested advantage of synbiotic over prebiotic or probiotic alone. 29 For radiation enteritis, one RCT failed to show significant improvement of prebiotic alone over placebo. 30 For prevention of developing necrotizing enterocolitis in very low birthweight infants, one RCT found probiotic alone and synbiotic decreased, but prebiotic alone did not decrease, versus placebo. 31 Although this statement was rejected, we felt that it should be presented to inform readers that based on available evidence, the clinical effect of prebiotics is not established. The evolution of this statement is also instructive. Our initial statement was "We cannot conclude whether adding prebiotics in a probiotic formulation, ie, a synbiotic, will provide additional clinical benefit compared with giving a probiotic." The pre-voting on this version of statement 4 was almost equally divided (31% accepted completely or with some reservation, 32% accepted with major reservation, 36% rejected completely or with reservation). We suspect that the way the initial statement was worded could have given rise to different interpretation. During the face-to-face discussion, panelists were in agreement that clinical evidence for prebiotics was weak. In order to reflect this, we felt that an unequivocal statement with clear unequivocal rejection would better serve to inform readers that the clinical benefit of prebiotics is yet to be proven. Comments. A total of 91% of votes cast in the pre-voting supported the statement, but only 52.94% of the post discussion votes were in support of the statement representing the misgivings of the panel regarding the evidence for benefit at this time. Several metaanalysis provide evidence that some probiotics have beneficial effect in IBS. However, one of the meta-analysis noted that the higher-quality studies reported a more modest treatment effect compared with lower-quality trials, and funnel plot asymmetry pointed to a potential publication bias towards studies with positive outcomes. 25 The panelists felt that it was important to recognize that not all probiotics have demonstrated benefit, and those that had reported benefit were not available in many of our countries. Notably, the panelists questioned whether a meta-analysis that placed together different formulations containing different strains in different strengths, using different trial designs in differing patient populations, was an appropriate method to address this clinical question. Furthermore, it was recognized that IBS is a heterogeneous condition; for example, while some patients experience constipation, others experience diarrhea and some experience predominantly abdominal pain while others predominantly bloating. Where a beneficial effect has been demonstrated, improvements in abdominal pain, bloating, and flatulence have been reported. 25 It remains unclear which species or combination was specifically effective for the different IBS subtypes. Thus, we believe that our judgment was fair despite the apparent high level of evidence and recommendation grade. A corollary would be that one would not accept a meta-analysis of all the various classes of antibiotics to treat all the different bacterial species, to make a statement that any antibiotic can be used to treat any bacterial infection. Comments. A total of 100% of votes cast in the pre-voting and 85.77% of the post discussion votes were in support of the statement. However, 64% of the respondents expressed some reservations about the current limited evidence from trials in support of this statement. A Cochrane systematic review on the management of pouchitis updated in 2015 included 13 studies involving 517 participants. 34, 35 However, studies on the role of probiotics were limited (acute pouchitis one trial, chronic pouchitis two trials, and prevention of pouchitis three trials). Nonetheless, there were two RCTs involving 76 patients with chronic pouchitis who achieved antibiotic-induced remission that clearly demonstrated treatment with VSL#3 maintained remission in the majority, while few or none did so on placebo. 36 Comments. A total of 100% of votes cast in the pre-voting and 100% of the post discussion votes were in support of the statement. However, 41% of the panelists expressed some reservations for the statement as current trials are small and may have lacked statistical power to show a true benefit. Future evidence may well change opinion in this field. In a Cochrane systematic review, there was no statistically significant benefit of probiotics for reducing the risk of relapse after medically or surgically induced remission, compared with maintenance therapy employing aminosalicylates or azathioprine. 38-43. However, all of the studies included small numbers of patients and may have lacked statistical power to show differences should they exist. Comments. The evidence for this proposed statement is mixed. A total of 68% of votes cast in the pre-voting and 52.94% of the post discussion votes were in support of the statement. At the same time, the statement was rejected by close to 18% at both pre-voting and post-discussion. A Cochrane metaanalysis performed in 2011 had not shown any benefit of probiotics in improving hepatic encephalopathy (HE). 44 An Indian unblinded RCT of 235 patients showed that 6 months of VSL#3 in cirrhotic patients with HE demonstrated equivalent efficacy with lactulose, both of which showed reduction of recurrent HE compared with placebo (27-34% vs 57%). 45 A blinded randomized controlled Indian study similarly using 6 months of VSL#3 on 130 cirrhotic patients with HE showed a trend towards reduction in breakthrough of HE compared with placebo (35% vs 52%, P = 0.12). The incidence of hospitalization was significantly reduced for HE (20% vs 42% P = 0.02) and cirrhotic complication (24% vs 45%, P = 0.034), compared with placebo. 46 The panelists cautioned against relying on a single-center trial showing benefit and advised waiting for more data. Comments. The evidence was graded level 1 based on a single randomized controlled study of 160 Indian patients with cirrhosis, and minimal HE were randomized to placebo versus VSL#3. Subjects on VSL#3 showed decreased incidence of HE (15% vs 26%, P < 0.05) with hazard ratio of 2.1 (95% confidence interval, 1.31-6.53) in favor of VSL#3. 47 This was associated with improvement in arterial ammonia, small intestinal bacterial overgrowth, orocecal transit time, increased psychometric HE scores, and increased critical flicker fusion thresholds, compared with baseline. Notwithstanding that the study was well conducted, the panelists reserved acceptance pending further confirmatory studies. A total of 63% of votes cast in the pre-voting and 37.5% of the post discussion votes were in support of the statement. At the same time, the statement was rejected by close to 19% at pre-voting and post-discussion. [44] [45] [46] [47] However, the panelists continue to recommend caution in this area as current evidence relies on data from many small trials with different protocols and probiotics used. Comments. Diarrhea is a common adverse effect in patients undergoing pelvic radiotherapy. This is due to the acute inflammatory changes of the small and large intestines within the radiation field. The intestinal microbiota and the luminal contents contribute to the homeostasis of the intestinal mucosa. Radiation perturbs the intestinal microbiota, mucosa permeability, and motility. Probiotic supplementation during pelvic radiotherapy reduces the incidence and severity of diarrhea. Therapeutic trials have used different combinations of Lactobacilli and Bifidobacterium as well as proprietary probiotic mixtures, for example, VSL3. They reduce bowel frequency and the need for anti-diarrheal medication. [48] [49] [50] [51] [52] A total of 82% of votes cast in the pre-voting and 80% of the post discussion votes were in support of the statement. Comments. A total of 82% of votes cast in the pre-voting and 69.23% of the post discussion votes were in support of the statement. This statement failed to obtain consensus. RCTs of probiotics in patients undergoing pelvic radiotherapy have not shown an increased incidence of infective events associated with bacterial strains found in the probiotics. [48] [49] [50] [51] [52] However, participants at the face-to-face meeting pointed out that there was still controversy about safety issues surrounding the use of probiotics in radiotherapy patients. Comments. Chemotherapy causes diarrhea in 20-40% of patients, which may significantly affect the quality of life of patients and which may lead to interruption of treatment. Chemotherapy may affect the composition of intestinal microbiota, which in turn affects the metabolism and immune function of the gut. Chemotherapy may also affect the intestinal mucosa barrier function and its permeability contributing to chemotherapy-induced diarrhea and microbial translocation. Few RCTs have been performed in patients undergoing chemotherapy. Different probiotics and probiotic mixtures have been used in these trials including different Lactobacillus and Bifidobactrium species and VSL#3. They have been shown to reduce bowel frequency, increase consistency of stools, and decrease the need for anti-diarrheal medication. [53] [54] [55] A total of 82% of votes cast in the pre-voting and 76.47% of the post discussion votes were in support of the statement. This statement failed to obtain consensus. Discussion centered around the heterogeneity of studied probiotic formulations, the absence of tested formulations in several Asian countries, and concerns with regard to potentially infectious causes of diarrhea and the risks of microbial translocation. Comments. Patients on chemotherapy may become neutropenic. Chemotherapy may also compromise the intestinal mucosal barrier and increase the risk of microbial translocation and hence the possibility of systemic infections. RCTs of probiotics in patients undergoing chemotherapy have not shown an increased number of infective events or increased frequency of antibiotic use in the probiotic treated patients. There have been reports of immunocompromised patients, including those undergoing chemotherapy, who have been infected with probiotic strains. However, there is no evidence that this takes place more frequently than with the native gut microbiota. 54, 55 A total of 50% of votes cast in the pre-voting and 68.75% of the post discussion votes were in support of the statement. This statement failed to obtain consensus. The greater than 30% rejection represent the panelists who remained concerned about safety based on anecdotal reports. The 18.75% increase in acceptance reflected a learning process, whereby some panelists appreciated that the evaluation of data should prioritize strong methodology (i.e. RCTs involving large sample sizes) over single case reports that do not take into account potential confounding factors. Comments. A total of 50% of votes cast in the pre-voting and 56.25% of the post discussion votes were in support of the statement. This statement failed to obtain consensus. Altered intestinal motility, increased levels of stress hormones, medications, and altered nutrient consumption may contribute to changes in gut microbiota. Firmicutes and Bacteroidetes decrease markedly in the intestines during critical illness, while there is an increased relative abundance of Proteobacteria.
56,57 Translocation of pathogenic bacteria may then contribute to infectious complications and to multiorgan failure seen in critically ill patients.
Probiotics may act to prime the dendritic cells of the immune system, produce bactericidal products that kill other pathogens, and inhibit the colonization of pathogenic bacteria. Several probiotics, probiotic combinations with and without prebiotics, and fecal microbiota transplant have been used in different populations of critically ill patients. [58] [59] [60] [61] [62] The available evidence in RCTs does not indicate an increased risk, but there are anecdotal reports that probiotics may worsen outcomes. 63 The current literature is not well equipped to answer questions on the safety of probiotic interventions with confidence as there appears to be a lack of systematic reporting of adverse events. Comments. The original iteration of this statement was "Probiotics are essential for the treatment of acute gastroenteritis (AGE) in children." Only 52% of the pre-voting was in support of the statement. Meta-analyses support efficacy of S. boulardii, Lactobacillus reuteri DSM 17938, and L. rhamnosus GG, in reducing the duration of diarrhea in childhood AGE. [64] [65] [66] While the efficacy is well supported, the issue debated pertained to cost-benefit considerations. Taking a broad perspective, it was observed that the reduction in duration of diarrhea was by 1-2 days. Several panelists voiced concerns with the additional costs of probiotics. As in the majority of childhood AGE are self-limiting and as rehydration is the mainstay of therapy, it was voiced by the pediatricians that this should be the priority in managing costs in less affluent populations. On the other hand, it was appreciated that parents may have socioeconomic considerations such as time off work and loss of income; the panel agreed that it was still important to draw attention to the benefit of probiotics. Therefore, it was decided to modify the statement to its current form and thus achieving 100% acceptance. Comments. This statement achieved 90% and 100% support in the pre-voting and the post-discussion, respectively. Antibiotic treatment may be associated with diarrhea, with dysbiosis as one of the possible mechanisms, and there is appeal in using probiotics to prevent antibiotic-associated diarrhea via restoration of the gut microflora. In a meta-analysis of 22 studies (n = 3898), probiotic use decreased the incidence of AAD in children (8% probiotic vs 19% placebo) with NNT of 10. 67 As the evidence was derived largely from studies with S. boulardii and L. rhamnosus GG, it may be premature to draw conclusions about efficacy and safety of other probiotic agents for pediatric AAD. , P = 0.9) and no differences in fecal soiling. 68 In another RCT involving 45 children with functional constipation, treatment with L. casei rhamnosus resulted in a reduction in abdominal pain (1.9 vs 4.8 episodes, P = 0.04) compared with magnesium oxide as a laxative, but there was no difference in treatment success at 4 weeks (78% vs 72%, P = 0.71) and in numbers of episodes of fecal soiling. Comments. A total of 86% of the pre-voting and 100% of the post-discussion votes were in support of the statement. Microbiota could increase harvesting of energy from the food and cause subclinical inflammation seen in metabolic disorders. 70 Alteration of the early infant gut microbiome has been correlated with the development of childhood obesity and type 1 diabetes. 71 The effectiveness of dietary interventions like breastfeeding and treatment with prebiotic and probiotic products is dependent on the stage of gut microbiota development, infant diet, and health status of both mother and infant. 72 In several RCTs, probiotics have been administered with the aim of targeting the microbiome during pregnancy to improve maternal and infant health, but the findings have often been confounded by mode of delivery, antibiotic use, ethnicity, infant sex, maternal health, and length of exposure. Two RCTs (n = 233) reporting on the effects of early probiotics administration in children aged 2-19 years failed to show benefit on one or more components of the metabolic syndrome. 73 Current evidence is insufficient to assess the effects of probiotics in reducing the risk of metabolic syndrome in children and adolescents.
Conclusions
Our primary objective was to address questions frequently asked by patients to their doctors. Our priority was to review the broad literature for the most relevant information that would provide insight to answer these questions. Where there were highly relevant and well-conducted studies, such as the various Indian studies in the areas of liver disease and inflammatory bowel disease, we have included them.
Our consensus differs from the Asia-Pacific consensus of Ghoshal et al. in the following respects. 74 Our primary aim was to educate the reader on the heterogeneity and variability in microbial species and quantity and quality of the various products that are labeled as probiotics. The topics covered in our review extended to liver diseases, immunocompromised patients, obesity, and common childhood bowel disorders. We envisaged that our document could be adapted to a list of simple questions and answers. Thus, it was our intention to produce clear unambiguous statements even if this led to a rejection. We suggest that the numbers of accepted and rejected statements represent in some way the current balance between the therapeutic potential and, more importantly, the limitations of probiotics in gastroenterology clinical practice.
